List of Small Molecule Pharmaceuticals Companies in France - 86

4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020. We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world. 4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.

Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanist ambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: ·      Using renewable raw materials ·      Relocate essential production and secure supply chains ·      Designing biocompatible products less toxic for the environment ·      Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms Because each customer has its own unique story and challenges, we cultivate a multidisciplinary, tailor-made approach. Science, economics, intellectual property, industrial realities: each of our answers is based on the best possible practices. Thanks to our advanced knowledge of micro-organisms, we combine chemistry and biology, paving the way for a more sustainable future. We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference

AB Science is a clinical-stage company designing and developing novel drugs to address diseases with a high unmet medical need, including inflammatory diseases, pathologies affecting peripheral and central nervous system and cancers. Our science is based on a highly integrated research network associating a state-of-the art drug discovery department to the highly valuable knowledge of our scientific committee’s members in order to develop original and innovative therapeutic strategies. This is illustrated by masitinib, our main clinical compound, which was designed as a disrupting mast-cells and glial-cells targeted therapy, through inhibition of key tyrosine kinase targets (c-Kit, CSF1R, FYN, LYN), which is currently developed in four therapeutic areas: neurology (amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s Disease), inflammatory diseases (mastocytosis, severe asthma), oncology (prostate cancer, pancreatic cancer) and viral diseases (Covid-19). AB Science intends to push therapeutic innovation forward with its second clinical compound AB8939 in oncology.

AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/

Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes. Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases should be available to patients of all ages.

Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases. Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments. These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology. Two initial drug candidates are already in clinical trials in indications with high unmet medical needs: • AEF0117, to treat disorders due to excessive cannabis use, has already provided evidence of efficacy in a phase 2a clinical study and has entered a phase 2b clinical trial in Q2 2022. • AEF0217, to treat various cognitive deficits, including those associated with Down syndrome (Trisomy 21), is currently being evaluated in phase 1 clinical trials, with no major adverse effects observed in the three patient cohorts treated to date. Phase 1/2 clinical studies with AEF0217 in Down syndrome subjects are expected to start in Q4 2022. These studies could provide initial efficacy results in H1 2023. Given the involvement of the CB1 receptor in numerous pathologies, Aelis Farma is also developing using its proprietary platform, several new CB1-SSi with differentiated pharmacological properties to target other brain pathologies. Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.

Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and tauopathies such as Progressive Supranuclear Palsy (PSP).

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. Our company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies. Please visit www.antabio.com and follow us on Twitter @antabio

Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com

BCI Pharma is an innovative bio-pharmaceutical company focused on small molecule drug discovery. We design innovative chemical libraries and our HTS platform can support your owned library synthesis. Founded by : - Dr. Dominique Surleraux who was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec). - Dr. Elisabeth Picou who had a position in a hospital, treating patients with infectious diseases.

BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis"​ (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.

bioMérieux develops in vitro products to diagnose infectious diseases, cancer and cardiovascular disease and to detect microorganisms in agri-foods, pharmaceuticals and cosmetics.BioFire COVID-19 test

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently. The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments. We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery. Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release. BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.

Bioprojet is a pharmaceutical laboratory committed to science and health. In the last 40 years, we’ve brought forward breakthrough medicines, helping patients struggling with challenging diseases. With passion and integrity, we follow the path set by Jeanne-Marie Lecomte and Jean-Charles Schwartz, founders of Bioprojet. At Bioprojet, we grow to keep honoring our motto : Passion for Research. Research for Patients.

BiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.

Cephagenix is focused on identifying and developing new effective migraine treatments

CERES BRAIN Therapeutics is dedicated to treat cerebral diseases with a first focus on rescuing suffering neurons with creatine through an innovative "creatine-to-brain" concept. The first indications are Creatine Transporter Deficiency syndrome, a disabling condition with no treatment affecting children and Amyotrophic Lateral Sclerosis. The lead compound CBT101 demonstrated efficacy in a preclinical models models as well as a large cerebral and neuronal distribution in primate. The CMC reached noticeable milestones with several GMP batches produced. Other mitochondriopathies are in the Ceres's pipeline. CERES BRAIN Therapeutics has already raised up to 12M€ to move towards the clinical program.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com

Corteria Pharmaceuticals - FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients. We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.

CSBio is a leading peptide and peptide synthesizer manufacturing company located in Silicon Valley, California. For over 30 years, CSBio has been producing automated peptide synthesizers, high quality custom peptides, and cGMP peptides for the global pharmaceutical community. Our peptide products and peptide synthesis equipment can be found in peptide production laboratories and pharmaceutical companies worldwide.

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.

CVasThera is a early clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for cardiovascular and bowel pathologies.

D&A PHARMA is a Specialty Pharma committed to providing effective and innovative treatments to patients suffering from various addictions (alcohol, opiates, cocaine…). In 2017, the treatment of alcohol and cocaine dependences is still an unmet medical need with more than 100 million patients worldwide suffering from their addictions, developing serious attributable diseases and creating significant burden. D&A PHARMA lead product, ALCOVER, is targeting the treatment of alcohol-dependent patients with a Very High Drinking Risk Level (daily alcohol consumption > 60g for women and > 100g for men). Life expectancy in this population is estimated at only 47 to 61 years, underlying the urgency to treat these patients. ALCOVER has shown to be effective and safe in both the detoxification phase and the long-term maintenance of alcohol abstinence with unprecedented efficacy results in this population. ALCOVER is approved in Italy and Austria and registration is ongoing in 10 other EU countries. Two other pharmacotherapies aiming at treating opiate and cocaine addictions respectively are under development with promising results. Our Culture, Values and Company's size foster a fast-paced, dynamic, forward-thinking, friendly and team-working environment. Look at our job opportunities and join us!

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

D.I.V.A. Expertise est une société de conseil, de stratégie et de développement en recherche scientifique dans les domaines de la Santé, de la Nutrition, de la Cosmétique et de l'Esthétique. Ses objectifs sont de soutenir les industriels dans la structuration, l'organisation et le développement de leur recherche afin d'optimiser ses coûts, délais et résultats. L'accompagnement personnalisé par nos experts dynamise le processus R&D d'un produit en promouvant Créativité, Innovation et Collaboration. Son cœur d'expertise est ciblé sur la biologie du tissu graisseux dit adipeux, reconnu comme organe endocrine avec un rôle fondamental et central sur l'homéostasie générale. Le partage de compétences, de valeurs scientifiques et humaines est à l'origine de la constitution de l'équipe de D.I.V.A. Expertise. A l'interface de quatre mondes Académique, Industriel, Médical et Chirurgical, D.I.V.A. Expertise a créé un réseau regroupant des experts multidisciplinaires et de renommée internationale dont elle assure l'animation et la coordination. D.I.V.A. Expertise (Développement, Innovation, Valorisation, Action en recherche) Ensemble, Embellissons la Recherche Pour plus d'informations, visitez notre site : www.diva-expertise.com Pour nous contacter, écrivez-nous : contact@diva-expertise.com

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Roughly 30-50% of NASH patients have CKD through common bidirectional pathways leading to severe renal impairment. Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor.

Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need.

At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.

Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50.

Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.

HEPHAISTOS-Pharma is a biotechnology company developing next generation immunotherapies against cancer. The company was co-founded in 2018 and has raised significant seed funding for its innovative work in cancer treatment.

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity. Please visit our webpage to know more about our products and offerings https://iktos.ai/products/

Immusmol develops small molecule antibodies for research, diagnostics and therapy. Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ... Compatible with existing antibody-based technologies, our small molecule antibodies can serve for: > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC. > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies). > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

INATHERYS is a biotechnology company that specializes in precision drug delivery systems for treating proliferative cancers through innovative ADC technology targeting CD71.

InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. IFB-088 is currently in phase 2 trial to treat ALS. Company History InFlectis BioScience has been founded by Dr. Philippe GUEDAT on August 30, 2013. He discovered IFB-088 (INN: icerguastat) in collaboration with an academic team at the MRC Laboratory of Molecular Biology (LMB) in Cambridge UK. Dr Philippe GUEDAT was awarded at the 2013 and 2014 National Competition of Business Startups using Innovative Technologies by the Ministry of Research in France. - 2013: Prize of Emergence section: €50k https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.annee_de_concours=2013&refine.region=Pays+de+la+Loire - 2014: Prize of Creation-Development section: €300k https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.region=Pays+de+la+Loire&refine.annee_de_concours=2014

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

KINNOV was created as a spin off from Greenpharma and Key-Obs, both located in Orléans, 100 km south of Paris France. Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people. KT-110 is the first project based on this new strategy to positively complete a phase 2 trial. KT-110 proof of concept clinical trial on alcohol addiction has started in nov 2019, results were available in January 2022. They were positive and very high risk level population is likely to be targeted for phase 3 study.

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. With most of its products indicated for serious and rare diseases, LFB is a major player in this area. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 5th worldwide and is also among the leading European companies for the development of new-generation proteins and treatments based on biotechnologies. With a sustained investment in research and development, the LFB Group bases its strategy on its international deployment and the design of innovative therapies.

MB Therapeutics is a pharmaceutical company that offer patient centric solutions to Develop and produce personalized medicines. MB Therapeutics solution is powered by 3D printing, allowing dosage, shape and API customization in GMP environement

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

Better Medicine for All MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition for achieving our objectives. #BetterMedicineForAll #ImpactHealth #GlobalHealth #ControlledRelease #CreativeThinking #InnovationForward #Science

Meletios Therapeutics’ aim is to fulfill the urgent and large unmet medical need for broad spectrum treatments against current and emerging viral infections. This French biotech company was created in April 2020 by a team of high level scientists and experienced biotech managers. One of our first drug candidate has confirmed its broad-spectrum potential in in vitro and in vivo models on the coronavirus family and influenza H1N1, demonstrating a dual antiviral and anti-inflammatory activity. This molecule will now be developed and tested in order to meet regulatory requirements and enter clinical phase II. Several drug candidates from Meletios portfolio are currently being tested both in vitro and in vivo and will expand our range of antiviral molecules on different RNA viruses. Meletios Therapeutics’ goal is to become a global leader in the fight against emerging viral infections by developing innovative broad-spectrum therapeutic solutions.

MElkin pharmaceuticals is a biopharmaceutical company identifying and developing innovative new treatments for cancer and brain diseases that are associated with aberrant activation of the MAPKinase/ERK signaling pathway. Founded in 2015, the company is currently engaged in the preclinical development of the PepFos lead compound for cancer treatment.

Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine. Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes. Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer. By viewing the human body through the lens of physics a new realm of possibilities has emerged.

NFL BIOSCIENCES clinically develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. It is delivered via two simple subcutaneous injections, administered one week apart, making patient compliance a breeze. There exists vast anecdotal evidence, from more than 10,000 smokers treated off-label in France with a predecessor product developed by the Pasteur Institute, that NFL-101 is safe and efficacious for total smoking cessation at twelve months. A Phase 1 clinical trial that reported data in 2017 confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking.

NH TherAguix is a biotech company registered at RCS Grenoble and based 19, Chemin des prés, 38240 Meylan

Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world. Our global growth strategy is focused on outstanding international collaborations and on our proprietary programs including those from our nitric oxide-donating research platform. For more information please visit www.nicox.com

Novaptech develops aptamer-based tools in the frame of technology transfer and innovation projects. Novaptech’s expertise is focused on the identification and the characterization of aptamers for biotechnological development of analytical and diagnostic aptamer projects. Novaptech develops collaborative projects or service agreements with academic laboratories and R&D department of companies. Novaptech works in close association with Dr. Toulmé ’s team, an academic laboratory (Inserm U1212, Bordeaux) which has more than 26 years of experience in aptamer selection.

OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com

Oncodesign Services is a Contract research organization (CRO) specializing in drug discovery and preclinical services. Founded in 1995, Oncodesign Services mission' is to contribute to the discovery of innovative therapies with unmet medical needs, in particular in oncology, inflammation and infectious diseases. From target identification, hit-to-lead and lead optimization to IND filing, Oncodesign Services support the R&D programs of customers globally (whether pharmaceutical companies, biotechs, public research institutions, etc.). Oncodesign Services offers a full spectrum of services in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, in vivo/In vitro pharmacology (including humanized models). This continuum enables, either as stand-alone (SOLO) or as integrated (DRIVE) programs, the drug discovery of small molecule, molecular radiotherapy and biologicals entities. As a pioneer in translational medicine to evaluate the efficacy of treatments, the company challenge relies on increasing throughput, minimizing timelines from bench to bedside while having a differential proposition of treatment for patients and therefore innovative science. For that, Oncodesign Services has been creating new technological pathways to find and select the best drug candidates. Oncodesign Services has BSL1, BSL2 and BSL3 laboratories and all sites maintain the full AAALAC international accreditation for our animal care and use program. Based in Dijon, France, in the heart of the university and hospital cluster, within the Paris-Saclay cluster and in Montreal, Canada, Oncodesign Services benefits from 15,000m² of fully equipped chemistry and biologic laboratories. Oncodesign Services has 230 employees in France, United Kingdom, Germany, Canada and the United States, with highly competent in discovery research and translational pharmacology.

Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.

‘OT4B was created in 2017, at the initiative of the French Prader-Willi community, to support and continue the academic research work of the team led by Professor Maithé Tauber from the National Reference Centre for Prader-Willi Syndrome at the Toulouse University Hospital*, and ongoing in France since 2007. In partnership with the Toulouse University Hospital, our objective is to develop oxytocin as the first treatment for patients with Prader-Willi syndrome and to make it available as soon as possible to the widest number of patients in order to improve the daily life and future of both patients and their families.’

OXELTIS is an independent medchem oriented service company managed by former researchers from Idenix Pharmaceuticals and located in Montpellier - France. Oxeltis is a company that delivers integrated solutions for managing and executing medicinal and fine organic chemistry projects. We run FTE programs (hit to lead optimization) with an expertise in some specialty chemistry such as macrocycles (pseudopeptides), mono & poly/oligosaccharides (sugar phosphates, iminosugars, saccharidic antigens…) nucleos(t)ides (modified nucleosides, phosphoramidites…), short peptides, linkers and PROTACs (Ligands E3 CRBN ligase library ) applied to discovery programs in oncology, antivirals and antibiotics mainly. OXELTIS client portfolio includes 40+ European and US companies from biotech to top 10 pharmaceutical companies. With its team of experienced medchem chemists, OXELTIS is proactive in providing rapid, high quality and competitive work. Specific expertise: - Contract research in medicinal chemistry, FTE programs for hit to lead optimization in different fields including antivirals, anticancer and antibiotics. - Fee-for-service custom synthesis expertise in heterocycles (in various fields), modified sugars (sugar phosphates, iminosugars, unnatural sugars…monosaccharides and oligosaccharides...), nucleoside/nucleotide (sugar and base-modified nucleosides, phosphoramidites…), macrocycles (e.g. antiviral antiproteases) . https://oxeltis.com/ https://twitter.com/Oxeltis_CRO

PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides.

Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de LAVENNE, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr. Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Perha Pharma focuses its research & development on two main programs: - Correction of cognitive deficits associated with Down syndrome: Trisomy 21 and Alzheimer's disease share a common therapeutic target involved in cognitive disorders, the DYRK1A protein kinase. The pharmacological inhibitors of this kinase optimized by Perha Pharma are derived from Leucettamine B, extracted from the Leucetta microraphis marine sponge. These molecules correct cognitive impairments observed in three mouse models of DS and three rodent models of AD. Leucettinib 21, our preclinical drug candidate, has been selected among over 500 synthesized Leucettinibs following a stringent multi-parameter go / no go decision tree. Perha Pharma is now preparing for regulatory preclinical studies. -Prevention of hearing loss induced by ototoxic drugs or noise: Perha Pharma-optimized molecules prevent hair cell apoptosis of the inner ear in cell models exposed to cisplatin. Perha Pharma is working at a proof-of-concept using rodents exposed to cisplatin or acoustic trauma.

Pharmaleads’ mission is to provide precision medicine to relieve the suffering associated with acute and chronic pain. Through the development of our proprietary Dual ENKephalinase Inhibitors (DENKI®) it is our aim to provide both efficacious and safe non-opiate pain therapeutics.

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glytone (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 9,600 employees in 44 subsidiaries and our distribution activities in 120 countries, our group generated €2.7 billion in revenues in 2022, 69% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. In 2020, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.

Pili, carbon conscious color company Pili is the leader in bio-based colorants and pigments. Its unique fermentation and sustainable chemistry processes, enable the production of high-performance, and low-carbon colors. Its technology aims at decarbonizing the color industry by drastically reducing the use of chemicals and fossil resources, particularly oil. Its products are designed for the textile, inks, paints & coatings and plastics sectors. Founded in 2015, Pili operates from 3 different sites: Toulouse White Biotechnology (TWB), Paris and the Roches-Roussillon industrial platform in Isère. With around 40 employees to date, the company has invested over €35 million since its launch to industrialize its innovative processes.

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Prestwick Chemical is a French provider of smart libraries. For almost 20 years, the company, founded by Prof. Camille-Georges Wermuth, has provided medicinal chemistry services and screening libraries to accelerate small molecules drug discovery. Prestwick has a large portfolio of smart Libraries designed to ensure maximal chemical diversity, possibly to access new IP while remaining within reach of both low and high throughput screening processes. They are constantly updated and improved. Our clients have reported high quality hit generation rate. The Prestwick Chemical Library®, a unique collection of 1520 small molecules (95% of approved off-patent drugs) is our flagship and is mentioned in 400+ publications worldwide. New innovative collections continuously feed our portfolio: Our Prestwick Drug-Fragment library has been designed to optimize the chance of success in Hit finding using Fragment-based Drug Discovery. Prestwick Chemical became a brand of Greenpharma in 2021.

Priothera - We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research.

“Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis. Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines. Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Tridek-One is a private biotechnology company founded in 2018, based on groundbreaking research by our scientific founders at INSERM, Paris on the role of CD31 in the modulation of the immune response. CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Developing agonists for ‘ITIM receptors’ has the potential to restore the immune balance without immunosuppression. Tridek-One demonstrated the ability of CD31 to modulate cells from both the adaptive and innate immune systems which makes it a unique and versatile target across diverse autoimmune and inflammatory disorders. Our company is financed by leading European investors and led by an experienced management team supported by renowned advisors.